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Abstract
Background: Solid tumors, such as hepato-pancreato-biliary cancer, develop tumor hypoxia with tumor growth.
Despite advances in surgery, a majority of these patients are in an unresectable condition. At this stage standard
cytotoxic chemotherapy regimens are applied with limited success. Novel biological treatment options based on an
antiangiogenic mechanism of action neglect other hypoxia mediated mechanisms (e.g. epithelial-mesenchymal
transition, Warburg effect, and immunological response) leading to an increased invasiveness with a poor outcome.
The novel antihypoxic molecule myo-inositoltrispyrophosphate (ITPP, OXY111A) acts as an allosteric effector of
hemoglobin and promotes normoxia in hypoxic tumors. In preclinical studies, tumor growth was reduced and
survival prolonged. Additionally, a beneficial side effect profile was observed.
Methods: In this first Ib/IIa clinical trial we will assess safety and tolerability of OXY111A as well as a proof of
concept regarding efficacy in patients with non-resectable primary and secondary tumors of the liver, pancreas, and
biliary tract. The study design is exploratory, prospective, open-labelled and mono-centric. The study is divided in a
dose escalation part with a maximum of 48 subjects and an extension part, in which 21 subjects will be included.
Discussion: The novel antihypoxic compound OXY111A has been tested in several cancer animal models showing
beneficial effects for both survival and low side effect profiles. This first in patient application of OXY111A will reveal
potential beneficial outcomes if anti-hypoxic therapy is added to standard cytotoxic treatment in patients with
primary and secondary hepatopancreatobiliary tumors.
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Background
Hypoxia occurs in almost any solid tumor beyond a
certain size and it crucial for the development and
progression of the disease [1]. The decreased oxygen
partial pressure modifies tumor behavior. Best known
is the increase in cancer-associated angiogenesis following
hypoxia. Novel anti-cancer agents (e.g. bevacizumab) have
been designed to specifically target the angiogenic re-
sponse with the aim to starve the tumor. However,
angiogenesis is only one part of the tumor's response
towards hypoxia [2].
Molecularly, hypoxia leads to the stabilization of HIF
(Hypoxia-Inducible Factors), transcription factors that
regulate the response of cancer cells to tumor hypoxia.
Apart from angiogenesis (e.g. via vascular endothelial
growth factor, VEGF), HIFs promote a number of pro-
cesses known to foster tumor development, including
inflammation (e.g. via the NF-κB pathway), a shift to gly-
colysis (Warburg effect, e.g. via up-regulation of glucose
transporter), invasive behavior (e.g. via Twist, an inducer
of the epithelial-mesenchymal transition), and malignant
potential (e.g. via OCT4 and other genes promoting a
stem cell phenotype). Furthermore, HIFs have been im-
plicated in the suppression of adaptive immunity and
the protection from cell death. Importantly, the presence
of hypoxia predicts a bad outcome for many tumor
types, consistent with the observation promoting ag-
gressive cancer behaviour (Fig. 1) [3]. Therefore, the
prevention of hypoxia in the first place may provide
an anticancer strategy superior to existing anti-angiogenic
approaches [2, 4].
OXY111A is a synthetic allosteric effector of hemoglobin
4. OXY111A is taken up by red blood cells via the band 3.1
transporter and promotes the dissociation of oxygen from
hemoglobin under conditions of low pO2. Thus, OXY111A
increases the oxygen-releasing capacity of hemoglobin spe-
cifically under hypoxic conditions [5] and has the potential
to prevent hypoxia without affecting the oxygen levels in
the surrounding normoxic cells. OXY111A is the first anti-
hypoxic compound without known, significant toxicities.
Thus far, OXY111A has been tested in five animal models
of cancer [6–10]. In a syngeneic, orthotopic rat model of
hepatocellular carcinoma, OXY111A prevented HIF1α
stabilization as well as VEGF production and increased the
apoptotic index, leading to a rapid reduction in tumor load
along with dramatically improved survival in treated ani-
mals. Consistent with this finding, OXY111A treatment is
generally associated with the inhibition of the hypoxic
tumor response in all models studied [5–10]. The concept
of vessel normalization through OXY111A has been im-
pressively confirmed in a syngeneic rat model of pancreatic
carcinoma and is of direct relevance to our patients [9].
Particularly important is the potentiation of chemotherapy,
which is very likely a consequence to vessel normalization.
Notably, no side effects were detected in all animal models,
including those where OXY111A was shown to improve
exercise capacity in healthy and sick mice [11].
The aim of this phase Ib/IIa clinical is to evaluate safety
and tolerability of OXY111A in order to determine a max-
imum tolerated dose (MTD) as well as a proof of concept
regarding efficacy in patients with primary or secondary
malignancies of the liver, pancreas and biliary tract.
Methods/Design
Study design
This is a phase Ib/IIa dose escalation and extension
study on the effects of OXY111A in patients suffering
from primary and secondary hepato-pancreato-biliary or
gastrointestinal malignancies not curable by surgical
means.
The study design is exploratory, prospective, open-
labelled and mono-centric. The study is divided in a
dose escalation part with a maximum of 48 subjects and
an extension part, in which 21 subjects will be included
(specifically 4 dose expansion groups of 6 patients each
determined by histology). Overall duration of an individ-
ual subject’s participation in the study is minimum 4 and
maximum 9 weeks (Fig. 2).
Dose escalation and extension
The aim of the escalation study part is the assessment of
additional preliminary safety and tolerability data for the
MTD. Safety will be assessed according to the (Common
Terminology Criteria for Adverse Events (CTCAE), also
Fig. 1 Effects of hypoxia in HPB tumors
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known as common toxicity criteria (CTC). These criteria
are issued by the US National Cancer Institute for the
standardized classification of adverse effects of drugs
used in cancer therapy. Specific symptoms and conditions
define each level of this classification system ranging from
1-5, where 1 is the mildest form of the specific symptom
and 5 is death. The CTCAE version used for this study
will be version 4.03.
According to CTCAE, Dose Limiting Toxicity (DLT)
will be defined as:
 any grade 5 toxicity
 any grade 4 neutropenia lasting >7 days
 any grade 3 febrile neutropenia, thrombocytopenia,
or anemia
 any grade 3 or 4 nonhematologic toxicity, excluding
alopecia, that is considered by the investigator to be
definitely, probably or possibly related to OXY111A.
A significant Treatment-Emergent Toxicity (TET) is
defined as any other grade 2 toxicity considered by the
investigator to be definitely, probably, or possibly related
to OXY111A, but not fulfilling the criteria for DLT.
Based on the assessment of DLT and TET the MTD
will be noted. MTD is defined as the dose preceding the
dose level at which one patient in the cohort experiences
a DLT during the treatment cycle, or the dose level at
which 3 or more patients experience a significant TET.
There are two factors to be considered for the
OXY111A dose escalation part of this study: total dose
administered and infusion rate. The human equivalent
dose-corrected No Observed Adverse Effect Level
(NOAEL) in rats was 15’000 mg/m2 once a week for
5 weeks, while it was 43’750 mg/m2 in minipigs also once
weekly (unpublished data obtained from Normoxys®).
From animal studies, hypernatremia is known to be asso-
ciated with high plasma concentrations typically encoun-
tered at the end of the OXY111A infusion and probably
associated with infusion rate. Therefore, infusion rates
of not more than 750 mg/m2/min are recommended.
According to available phase I data in healthy volun-
teers (unpublished data obtained from Normoxys®),
cohort 1 starts at a dose close to 5’600 mg/m2
weekly, i.e. 1866 mg/m2 thrice weekly. Dose escalation
is performed according to the following scheme up to
a maximum calculated dose of 43’700 mg/m2 weekly,
which corresponds to the NOAEL level administered
once weekly in minipigs.
Table 1 schedules dose escalation. In each cohort, 3
patients will be included (Table 1).
No more than 6 patients (3 + 3 patients) will receive
the same dose during the dose escalation phase accord-
ing to the following rules.
1. Dose escalation to the subsequent cohort is possible
if there is no DLT and no significant TET.
2. If 1 DLT occurs, the ongoing cohort will be stopped,
and another three patients will receive the next
lower dose level tested, if only 3 patients have
received this lower dose. If already 6 patients have
received this lower dose, this lower dose represents
MTD. If DLT occurs in cohort 1, the dose will be
reduced to 4’200 mg/m2 weekly (ie. to 75 %), and
this dose will be tested in 3 patients.
3. If a 1-2 significant TETs occur, another three pa-
tients will receive the same dose.
4. If out of 6 patients with the same dose, 3 or more
significant TETs occur, this dose level will be the MTD.
5. If out of 6 patients, 1-2 experience significant TETs,
the dose may be increased to the next dose escal-
ation step as shown in Table 1 in 3 additional pa-
tients. However, if a DLT has been observed, this
dose must not be administered again.
Following these rules, a maximum of 48 patients are
included in the dose escalation phase of the study. As
soon as the MTD during the “dose escalation” phase is
defined, a “dose extension” is performed in additional 21
subjects, who will receive the MTD.
In parallel, a maximum of three patients receiving the
same dose of the IMP will be included in the study. De-
pending on the safety and tolerability of the compound,
the next patient (or maximal the next three patients)
who receives a higher dose, will be included after the last
patient completed the whole IMP cycle (with a total of 9
applications) receiving the last lower dose.
Fig. 2 Study flow chart
Table 1 Dose escalation scheme
Cohort No. Weekly Dose Single Dose Total Dose
(9 applications )
% Dose
Escalation
1 5'598 mg/m2 1'866 mg/m2 16'794 mg/m2 baseline
2 11'196 mg/m2 3’732 mg/m2 33'588 mg/m2 100 %
3 16'800 mg/m2 5‘600 mg/m2 50‘400 mg/m2 50 %
4 21‘000 mg/m2 7‘000 mg/m2 63‘000 mg/m2 25 %
5 26‘250 mg/m2 8‘750 mg/m2 78‘750 mg/m2 25 %
6 31‘500 mg/m2 10‘500 mg/m2 94‘500 mg/m2 20 %
7 37‘170 mg/m2 12'390 mg/m2 111‘510 mg/m2 18 %
8 43'500 mg/m2 14'500 mg/m2 130'500 mg/m2 ~17 %
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A classical 3 + 3 phase I design was chosen for the dose
escalation part of the study, because there is insufficient
information on safety and tolerability of doses above
5’600 mg/m2 once weekly and of repeated doses in
humans (unpublished data obtained from Normoxys®).
This design induced the least toxicities in a simulation
study comparing various dose finding escalation strategies
and therefore appears to be most appropriate for a study
using such substance in terminally ill cancer patients,
where the therapeutic benefit is yet unknown.
The infusion rate must not be above 750 mg/m2/min.
In order to achieve this, a constant infusion rate at 1/10
of the NOAEL infusion rate is chosen: an infusion
rate of 75 mg/m2/min is scheduled for all dose steps.
Due to the short half-life of OXY111A and the pro-
posed mechanism of action, a slow, constant infusion
over several hours appears more promising than a
short infusion leading to excessively high concentrations
of the compound.
Study population and number of patients
Patients with primary and secondary hepato-pancreato-
biliary and gastrointestinal neoplasia will be assessed for
eligibility at the interdisciplinary tumor board of the
Swiss HPB Center. Patient information and informed
consent will be obtained in the outpatient and inpatient
hospital setting. Overall, a maximum of 69 patients will
be included consisting of maximum of 48 in the dose es-
calation and 21 patients in the extension part of the
study. OXY111A will be administered in an outpatient
setting in the Phase I unit of the Clinical Trials Center
of the University Hospital Zurich, in which the study
equipment is reserved for this study explicitly. Appropri-
ate back up material will be available in case of technical
dysfunction. The study is planned to be completed
within approximately two years.
Inclusion criteria
Participants fulfilling all of the following inclusion criteria
are eligible for the study:
 Informed Consent as documented by signature
 Patients diagnosed for non-resectable hepato-
pancreato-biliary or gastrointestinal neoplasm
 Male and Female patients ≥ 18 years of age
 Eastern Cooperative Oncology Group (ECOG)
performance status score of ≤ 2 at study entry.
 A life-expectancy of >3 months
 Adequate hematologic function, as defined by
○ an absolute neutrophil count of >1000/mm3
○ a hemoglobin level of >10 g/dL
○ a platelet count of >100,000/mm3
 Adequate renal function, as defined by a serum
creatinine level of ≤1.5 x the upper normal limit.
 Use of effective contraception. Female patients who
are surgically sterilized/hysterectomized or post-
menopausal for longer than 2 years are not considered
as being of procreative potential.
 Adequate recovery from recent surgery,
chemotherapy and radiation therapy. At least
28 days must have been elapsed from major surgery,
prior chemotherapy, prior treatment with an
investigational agent or device, or prior radiation
therapy (palliative radiation therapy is allowed).
 Accessible for treatment and follow-up. Patients
enrolled in this trial must be treated at the
participating center.
Exclusion criteria
The presence of any of the following exclusion criteria will
lead to exclusion of the potentially eligible participant:
 Contraindications to the class of drugs used in this
study, e.g. known hypersensitivity or allergy to class
of drugs or the investigational product
 Women who are pregnant or breast feeding
 Intention to become pregnant during the course of
the study
 Lack of safe contraception, defined as: Female
participants of childbearing potential, not using and
not willing to continue using a medically reliable
method of contraception for the entire study
duration, such as oral, injectable, or implantable
contraceptives, or intrauterine contraceptive devices,
or who are not using any other method considered
sufficiently reliable by the investigator in individual
cases. Please note that female participants who are
surgically sterilised / hysterectomised or post-
menopausal for longer than 2 years are not consid-
ered as being of child bearing potential.
 Other clinically significant concomitant disease
states (e.g., renal failure, hepatic dysfunction,
cardiovascular disease, etc.)
 Known or suspected non-compliance, drug or alco-
hol abuse
 Inability to follow the procedures of the study, e.g.
due to language problems, psychological disorders,
dementia, etc.
 Participation in another study with investigational
drug within the 30 days preceding and during the
present study
 Previous enrolment into the current study
 Enrolment of the investigator, his/her family
members, employees and other dependent persons.
Assessment of primary outcome
The primary outcome, safety and tolerability (establishing
MTD) of the investigational medical product (IMP) will
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be assessed at every application for each patient. According
to the 3 + 3 dose escalation schedule, after each patient, a
decision on the continuation will be taken, i.e. to either
add an additional patient in the same cohort or to continue
with the next cohort after three patients.
Assessment will be done using CTCAE. The obtained
data will be added to the electronic case report form
(eCRF) using the software secuTrial® (interActive Systems
GmbH (iAS), Berlin/Germany).
Assessment of secondary outcomes
Secondary outcome focuses on efficacy as measured by
means listed below:
 Imaging assessment by 18-Fluorodeoxyglucose and
Positron Emission Tomography (18 F-FDG PET) in
FDG-avid tumors and Magnetic resonance imaging
(MRI) in non-FDG avid tumors.
○ 18F-FDG PET: Response evaluated by Response
Evaluation Criteria In Solid Tumors (RECIST) 1.1
and European Organization for Research and
Treatment of Cancer (EORTC) criteria
○ MRI: Response evaluated by RECIST 1.1.
 Peripheral blood serum for safety and efficacy (e.g.
tumor markers)
 Tumor biopsy if possible for histopathological
examination.
Pharmacokinetics
Blood samples are taken before OXY111application as
well as at 3 and 6 hours after application start and 30 mi-
nutes, 1, 2 and 40 hours following application. Plasma
levels of OXY111A are measured by Swiss BioAnalytics
AG (Birsfelden, Switzerland) under ICH Good Laboratory
Practice (GLP) conditions and validated by Food and Drug
Administration (FDA) and European Medicines Agency
(EMA) guidance [12].
Ethics
This study is conducted under the principles of the Dec-
laration of Helsinki and International Conference on
Harmonisation E6 Good Clinical Practice (ICH E6 GCP)
guidelines. The study protocol has been approved by the
independent medical ethics committee of canton Zurich
(Kantonale Ethikkommission Zürich, Switzerland, KEK-
ZH-Nr. 2014-0374) and the Swiss regulatory authority
Swissmedic (2015DR1009). The study protocol has been
registered on an international primary trial register
(ClinicalTrials.gov Identifier: NCT02528526).
Discussion
The aim of this trial is to assess the novel antihypoxic
compound OXY111A in patients with non-resectable
primary and secondary tumors of the liver, pancreas and
biliary tract. Hepato-pancreato-biliary and gastrointestinal
tumors, as known for solid tumors, develop hypoxia with
consecutive modification of hypoxia dependent pathways
[1]. Despite several advantages in drug development
regarding tumor angiogenesis, many other hypoxic
mechanisms have not been addressed so far [2]. The
novel antihypoxic compound OXY111A has been
tested in several cancer animal models showing beneficial
effects for both survival and low side effect profiles
[6–10].In this phase Ib/IIa clinical trial, application of
OXY111A will be evaluated in patients with primary
and secondary HPB tumors focussing on safety and
tolerability, as well as efficacy.
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